Accelerated Path to Cures
Editat de Josep Bassaganya-Rieraen Limba Engleză Hardback – 9 mai 2018
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 357.61 lei 6-8 săpt. | |
Springer International Publishing – 12 ian 2019 | 357.61 lei 6-8 săpt. | |
Hardback (1) | 364.33 lei 6-8 săpt. | |
Springer International Publishing – 9 mai 2018 | 364.33 lei 6-8 săpt. |
Preț: 364.33 lei
Preț vechi: 383.50 lei
-5% Nou
Puncte Express: 546
Preț estimativ în valută:
69.73€ • 72.52$ • 58.44£
69.73€ • 72.52$ • 58.44£
Carte tipărită la comandă
Livrare economică 13-27 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783319732374
ISBN-10: 3319732374
Pagini: 73
Ilustrații: VIII, 82 p. 11 illus. in color.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.31 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
ISBN-10: 3319732374
Pagini: 73
Ilustrații: VIII, 82 p. 11 illus. in color.
Dimensiuni: 155 x 235 x 14 mm
Greutate: 0.31 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland
Cuprins
Chapter 1: Introduction to Accelerated Path to Cures and Precision Medicine in Inflammatory Bowel Disease.- Chapter 2: Computer-Aided Drug Discovery.- Chapter 3: Preclinical Studies: Efficacy and Safety.- Chapter 4: From Nutritional Immunology to Drug Development.- Chapter 5: Development of Synthetic Patient Populations and In Silico Clinical Trials.
Notă biografică
Dr. Josep Bassaganya-Riera is a serial entrepreneur and innovator who has served as the Director of the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) at the Biocomplexity Institute of Virginia Tech since 2002. The NIMML tackles unsolved challenges in complex human diseases with unmet clinical needs. His research has received over $55 million in competitive R&D funding to combine advanced computational technologies with preclinical and clinical experimentation. The NIMML translates novel scientific discoveries into commercial applications that address unmet patient or consumer needs. Dr. Bassaganya-Riera has published over 150 peer-reviewed publications in reputable biomedical journals, founded 3 successful biotech companies (Pervida, Biotherapeutics and Landos Biopharma), and was recently named 2017 Innovator of the Year by the Roanoke-Blacksburg Technology Council. Dr. Bassaganya-Riera, and his companies have been active members of a statewide group that supports the planning behind the Governor’s 2015 Virginia Bioscience Initiative. This initiative calls for Virginia to be in the top three pharmaceutical regions by 2023. Dr. Bassaganya-Riera was a featured presenter at the Governor’s Forum on Bio and Big Data.
Textul de pe ultima copertă
Accelerated Path to Cures provides a transformative perspective on the power of combining advanced computational technologies, modeling, bioinformatics and machine learning approaches with nonclinical and clinical experimentation to accelerate drug development. This book discusses the application of advanced modeling technologies, from target identification and validation to nonclinical studies in animals to Phase 1-3 human clinical trials and post-approval monitoring, as alternative models of drug development. As a case of successful integration of computational modeling and drug development, we discuss the development of oral small molecule therapeutics for inflammatory bowel disease, from the application of docking studies to screening new chemical entities to the development of next-generation in silico human clinical trials from large-scale clinical data. Additionally, this book illustrates how modeling techniques, machine learning, and informatics can be utilized effectively at each stage of drug development to advance the progress towards predictive, preventive, personalized, precision medicine, and thus provide a successful framework for Path to Cures.
Caracteristici
Details the role of modeling and computational approaches in precision medicine Highlights the progress towards precision medicine Advances Path to Cures